Abstract:BACKGROUND AND AIMS:Accurate assessment of the risk of mortality following a cirrhosis-related admission can enable health-care providers to identify high-risk patients and modify treatment plans to decrease the risk of mortality.METHODS:We developed a post-discharge mortality prediction model for patients with a cirrhosis-related admission using a population of 314,292 patients who received care either at Massachusetts General Hospital (MGH) or Brigham and Women's Hospital (BWH) between 1992 and 2010. We extracted 68 variables from the electronic medical records (EMRs), including demographics, laboratory values, diagnosis codes, and medications. We then used a regularized logistic regression to select the most informative variables and created a risk score that comprises the selected variables. To evaluate the potential for generalizability of our score, we applied it on all cirrhosis-related admissions between 2010 and 2015 at an independent EMR data source of more than 18 million patients, pooled from different health-care systems with EMRs. We calculated the areas under the receiver operating characteristic curves (AUROCs) to assess prediction performance.RESULTS:We identified 4,781 cirrhosis-related admissions at MGH/BWH hospitals, of which 778 resulted in death within 90 days of discharge. Nine variables were the most effective predictors for 90-day mortality, and these included all MELD-Na's components, as well as albumin, total cholesterol, white blood cell count, age, and length of stay. Applying our nine-variable risk score (denoted as "MELD-Plus") resulted in an improvement over MELD and MELD-Na scores in several prediction models. On the MGH/BWH 90-day model, MELD-Plus improved the performance of MELD-Na by 11.4% (0.78 [95% CI, 0.75-0.81] versus 0.70 [95% CI, 0.66-0.73]). In the MGH/BWH approximate 1-year model, MELD-Plus improved the performance of MELD-Na by 8.3% (0.78 [95% CI, 0.76-0.79] versus 0.72 [95% CI, 0.71-0.73]). Performance improvement was similar when the novel MELD-Plus risk score was applied to an independent database; when considering 24,042 cirrhosis-related admissions, MELD-Plus improved the performance of MELD-Na by 16.9% (0.69 [95% CI, 0.69-0.70] versus 0.59 [95% CI, 0.58-0.60]).CONCLUSIONS:We developed a new risk score, MELD-Plus that accurately stratifies the short-term mortality of patients with established cirrhosis, following a hospital admission. Our findings demonstrate that using a small set of easily accessible structured variables can help identify novel predictors of outcomes in cirrhosis patients and improve the performance of widely used traditional risk scores.

HDL-C Levels Added to the MELD Score Improves 30-Day Mortality Prediction in Asian Patients with Cirrhosis

Prediction Value of Model for End-Stage Liver Disease Scoring System on Prognosis in the Acute on Chronic Liver Failure Patients with Plasma Exchange Treatment.

Evidence-based Incorporation of Key Parameters into MELD Score for Acute-on-chronic Liver Failure

Model for End-Stage Liver Disease Score Predicts the Mortality of Patients with Coronary Heart Disease Who Underwent Percutaneous Coronary Intervention

Establishment of Prognostic Scoring Models for Different Etiologies of Acute Decompensation in Hospitalized Patients with Cirrhosis

The MELD-Plus: A Generalizable Prediction Risk Score in Cirrhosis

A Modified Meld Model For Chinese Pre-Aclf And Aclf Patients And It Reveals Poor Prognosis In Pre-Aclf Patients

High-density Lipoprotein Cholesterol is a Predictor of Survival in Cirrhotic Patients with Acute Gastrointestinal Bleeding: a Retrospective Study

Hepatic Encephalopathy and Spontaneous Bacterial Peritonitis Improve Cirrhosis Outcome Prediction: A Modified Seven-Stage Model as a Clinical Alternative to MELD

[Study of 109 cases of purulent pleurisy in infants less than a year old].

Prognostic Utility of Novel Biomarkers in Acute-on-chronic Liver Failure (ACLF) Associated with Hepatitis B: A Multicenter Prospective Study.

Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and spontaneous bacterial peritonitis.

Assessing the Prognostic Performance of the Child-Pugh, Model for End-Stage Liver Disease, and Albumin-Bilirubin Scores in Patients with Decompensated Cirrhosis: A Large Asian Cohort from Gastroenterology Department

A Validated Composite Score Demonstrates Potential Superiority to MELD-Based Systems in Predicting Short-Term Survival in Patients with Liver Cirrhosis and Spontaneous Bacterial Peritonitis—A Preliminary Study

A Novel Integrated Model for End-Stage Liver Disease Model Predicts Short-Term Prognosis of Hepatitis B Virus-Related Acute-on-chronic Liver Failure Patients.

Prognosis Prediction Performs Better in Patients with Non-Cirrhosis Hepatitis B Virus-Related Acute-on-chronic Liver Failure Than Those with Cirrhosis.

Application of model for end-stage liver disease as disease classification in cardiac valve surgery: a retrospective study based on the INSPIRE database

Model for end-stage liver disease-3.0 vs. model for end-stage liver disease-sodium: mortality prediction in Korea

Meld-Na Score Predicts Major Cardiovascular Events, in Individuals with Nonalcoholic Fatty Liver Disease

Development and Validation of a Non-Invasive Model for Predicting Liver Cirrhosis in Patients with Chronic Hepatitis B

Validation of Prognostic Scores to Predict Short-Term Mortality in Patients with HBV-related Acute-on-chronic Liver Failure